Alliance Pharma (APH)

 

APH Share PerformanceMore

52 week high71.00 25/01/18
52 week low44.75 28/02/17
52 week change 17.65 (35.48%)
4 week volume13,461,661 27/01/18
price67.40
price date1519295946
close66.00

Latest NewsMore

Total Voting Rights

RNS Number: 3841E Alliance Pharma PLC 08 February 2018 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Total Voting Rights Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 January 20...

Notification of Major Holdings

RNS Number: 3838E Alliance Pharma PLC 08 February 2018 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Alliance Pharma plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the n...

Notification of Preliminary Results

Notification of the date financial results will be published

Hardman Research: Strong Operational Cashflow

RNS Number: 2053D Alliance Pharma PLC 29 January 2018 Hardman Research: Strong Operational Cashflow 2017: strong operational cashflow - Alliance Pharma is continuing with its buy-and-build strategy having evolved through 35 acquisitions over a period of 20 years into a profitable, cash- generative, specialty pharma business. The company has a mix of inter...

Pre-Close Trading Update

RNS Number: 4469C Alliance Pharma PLC 22 January 2018 For immediate release 22 January 2018 ALLIANCE PHARMA PLC ("Alliance" or the "Group") Pre-Close Trading Update Alliance Pharma plc (AIM: APH), the specialty pharmaceutical group, announces its pre-close trading update ahead of the announcement of its preliminary results for the year ended 3...

Acquisitions to boost Alliance Pharma prospects, says Hardman

Hardman Research has issued a report on Alliance Pharma. It says: 'Alliance Pharma is continuing with its buy-and-build ...

Hardman Research: Acquisitions to boost growth

RNS Number: 5498B Alliance Pharma PLC 11 January 2018 Hardman Research: Acquisitions to boost growth prospects Acquisitions to boost growth prospects - Alliance Pharma is continuing with its buy-and-build strategy, having evolved through 35 acquisitions over a period of 20 years into a profitable, cash generative, specialty pharma business. The company has a...

Total Voting Rights

RNS Number: 7423A Alliance Pharma PLC 02 January 2018 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Total Voting Rights Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 29 December ...

Fundamental DataMore

P/E ratio17.506
EPS3.85
Dividend yield1.795 %

Latest discussion posts More

  • Re: Is that it for now?

    You might be right, you might be wrong. Markets are certainly overvalued, a retrace is due, when it comes it may indeed be a sharp one, but then again it may not amount to ...
    1-Feb-2018
    winningstreak
  • Is that it for now?

    Over the last week or so I get the feeling that markets are looking to retrace. Good companies look overvalued and poor companies are starting to look overvalued too. I ...
    1-Feb-2018
    NoQuestionMarks
  • Re: Vamousse

    Share price now above 70p, I am pleased but not surprised to see that. APH is the largest holding in my portfolio. I feel safe with APH, as the demand for medicines (niche ...
    23-Jan-2018
    winningstreak

Users' HoldingsMore

Users who hold Alliance Pharma also hold..
XP POWER100%
LENOVO100%
CITY MERCH.HIGH100%
3I GRP.100%
RENISHAW100%

Codes & Symbols

ISINGB0031030819
SymbolsAPH, LSE:APH, APH.L, APH:LN, LON:APH, XLON:APH

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account